Australian real-estate loan volumes hit rock bottom this week, while Indonesian syndicated loans are down 37%, despite Charoen Pokphand Indonesia securing $320 mln.
The task facing the bank's Australia and New Zealand CEO is to revitalise the franchise after several high-level departures and a corruption scandal in China.
Beijing-based Hony Capital is buying an additional 6.5% stake in Santos for A$500m as part of the Australian oil and gas producer's broader efforts to shore up its balance sheet.
Nominations are now open for FinanceAsia's 2015 Achievement Awards for Australia and New Zealand. Here is how to submit.
Nippon Life Insurance is dipping into its warchest to purchase an 80% stake in NAB's life insurance business.
Allen will wear two hats for the US bank, becoming head of investment banking whilst remaining head of general industries and financial sponsors.
Market volatility prompts bankers to repackage IPOs, with downward price adjustments an obvious sign of the times.
The French bank has identified infrastructure finance as a growth area for the franchise and reckons the advisory will complement existing resources and energy teams in Sydney.
At a roundtable in Sydney fund managers talk to New South Wales treasurer Gladys Berejiklian about structuring infrastructure deals to mitigate risk.
Maintaining profit momentum will be a struggle for Australia’s banks as the economy changes gear and regulators apply the brakes.
Private Asian capital is increasingly competing with institutional investors for big real estate deals globally.
Poll shows nearly 40% of Asia-based bond investors now hold a significant share of their portfolios in Australian and New Zealand dollar debt securities.
Asia-based bond investors want Australian and New Zealand dollar borrowers to issue larger average deals, according to a survey by FinanceAsia and NAB.
A free-trade deal between Beijing and Canberra is making it easier for Chinese companies and individuals to acquire assets in Australia.
The Chinese baby formula maker's deal for Australia's Swisse Wellness shows SOEs have rivals for overseas M&A targets. But some wonder if Biostime is fighting above its weight.